彭布罗利珠单抗
医学
内科学
肿瘤科
成本效益
中止
化疗
癌
食管鳞状细胞癌
免疫疗法
癌症
风险分析(工程)
作者
Xuan Song,Zhiwei Zheng,Xiuli Li,Hongfu Cai,Longfeng Zhang
标识
DOI:10.2217/cer-2021-0112
摘要
Aim: This study aimed to evaluate the cost-effectiveness of pembrolizumab compared with that of chemotherapy in the second-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients with a combined positive score ≥10. Methods: A Markov model was established to compare the lifetime costs and quality-adjusted life years (QALYs) of different treatment options. Sensitivity analysis was performed to test the stability of the model. Results: The increased utility and cost of pembrolizumab were 0.442 QALYs and US$11,826.79 compared with those of chemotherapy. The incremental cost-effectiveness ratio was US$26,757.45/QALY, which was less than the threshold of three-times the GDP per capita. The prices of paclitaxel and pembrolizumab were the most important influencing factors. Conclusion: Pembrolizumab is a cost-effective second-line treatment of ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI